Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

20.36 +1.53 (+8.13%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
Exposures Product Safety
Smart Money Is Betting Big In HIMS Options
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Disrupting pharmacies is just the start for Hims & Hers. 
Via The Motley Fool
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers. 
Via The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
A Look Into Hims & Hers Health Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
This Is What Whales Are Betting On Hims & Hers Health
Via Benzinga
Decoding 6 Analyst Evaluations For Hims & Hers Health
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
Via Benzinga
Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. 
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
What Is Going On With Hims & Hers Stock?
Big GLP-1 news could have an impact. 
Via The Motley Fool
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
Where Does Hims & Hers Stock Go From Here?
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? 
Via The Motley Fool
Exposures Product Safety
2 Incredibly Cheap Growth Stocks to Buy Right Now
Look beyond the stock price at the business when shares are volatile. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Consistently investing even moderate sums can grow your portfolio with time. 
Via The Motley Fool
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
Exposures Product Safety
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
Growth for its GLP-1 weight loss drugs continues to be robust. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week. 
Via Benzinga
Topics Stocks
Exposures US Equities
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over... 
Via Benzinga
Exposures Product Safety
Massive News for Hims & Hers Stock: The Truth About Today's Move
Hims & Hers may not be hurt by GLP-1 news the way investors think. 
Via The Motley Fool
2 Winning Growth Stocks That Are Screaming Buys Right Now
These top stocks are on a winning streak and have the businesses to keep it going. 
Via The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.